MGMT and glioma: Furthermore, for recurrent gliomas, standard-of-care treatments are not well defined; treatment is usually selected based on prior therapy, age, Karnofsky Performance Scale (KPS), MGMT promoter methylation status, and patterns of disease progression (26).